| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8630047 | Diabetes Research and Clinical Practice | 2018 | 24 Pages |
Abstract
SGLT2 inhibitors are safe, but mildly reduce the HbA1c level. The clinical significance of SGLT2 inhibitors in the target population was limited.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Lin Zhang, Mei Zhang, Qingguo Lv, Nanwei Tong,